Related references
Note: Only part of the references are listed.Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
Sandro Pignata et al.
LANCET ONCOLOGY (2023)
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Ramez N. Eskander et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Cancer statistics, 2023
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2023)
PD-L1 in circulating exosomes of Merkel cell carcinoma
Anais Zanella et al.
EXPERIMENTAL DERMATOLOGY (2022)
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
David M. O'Malley et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
V Makker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
The Changing Landscape of Gynecologic Cancer Mortality in the United States
Angela N. Giaquinto et al.
OBSTETRICS AND GYNECOLOGY (2022)
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study
Ana Oaknin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Cause, Epidemiology, and Histology of Polyps and Pathways to Colorectal Cancer
Brian A. Sullivan et al.
Gastrointestinal Endoscopy Clinics of North America (2022)
Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine
Nicolas Huyghe et al.
CANCERS (2022)
Exploring immunotherapy in colorectal cancer
Junyong Weng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990?2019
Baoxia Gu et al.
GYNECOLOGIC ONCOLOGY (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis
Shaily Arora et al.
CLINICAL CANCER RESEARCH (2020)
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer The Canadian Cancer Trials Group CO.26 Study
Eric X. Chen et al.
JAMA ONCOLOGY (2020)
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)
David S. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
C. Luchini et al.
ANNALS OF ONCOLOGY (2019)
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
Francois Ghiringhelli et al.
FRONTIERS IN IMMUNOLOGY (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells
Zibing Wang et al.
ONCOIMMUNOLOGY (2017)
Landscape of Microsatellite Instability Across 39 Cancer Types
Russell Bonneville et al.
JCO PRECISION ONCOLOGY (2017)
Endometrial cancer: Not your grandmother's cancer
Jessica N. McAlpine et al.
CANCER (2016)
Microsatellite Instability as a Biomarker for PD-1 Blockade
Jonathan C. Dudley et al.
CLINICAL CANCER RESEARCH (2016)
The Immune Biology of Microsatellite-Unstable Cancer
Matthias Kloor et al.
TRENDS IN CANCER (2016)
PD-1, PD-L1 expression in 1599 gynecological cancers: Implications for immunotherapy
T. J. Herzog et al.
GYNECOLOGIC ONCOLOGY (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method
Joanna IntHout et al.
BMC MEDICAL RESEARCH METHODOLOGY (2014)
Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy
Anke Vanderstraeten et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
Effects of conventional therapeutic interventions on the number and function of regulatory T cells
Mario Roselli et al.
ONCOIMMUNOLOGY (2013)
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
W. Joost Lesterhuis et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+T-Cell Infiltration and Survival of Patients with Cervical Carcinoma
Rezaul Karim et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel - long-term follow-up
B. Sorbe et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)